Fig. 1.

Schematic of the CD3/CLDN18.2 XFab^® bispecific antibody (AHT-102). AHT-102 is designed with the anti-hCD3e variable heavy chains and variable light chains fused to anti-hCLDN18.2 Fab frameworks (anti-hCLDN18.2 Fab binds human and mouse CLDN18.2, respectively, and is from Beijing Immunoah Pharma Tech). This fusion is facilitated by an IgG1 hinge region, which includes a deletion mutation at the C266 position, and is situated at the C-terminus of the Fab frameworks. This schematic representation details the structural composition and genetic modifications that enable the dual targeting mechanism of AHT-102, optimizing its efficacy in recognizing and binding to both CD3 on T cells and CLDN18.2 on tumor cells